This has been a September to remember for the biotech industry.
Just before the month opened, Novartis won a pioneering — and ahead-of-schedule — FDA approval with a CAR-T for blood cancer. And the news has just kept on rolling in from there, from Alnylam’s hit on its rare disease RNAi therapy to Axovant’s stock-crushing miss on Alzheimer’s.
On the last day of the month, we fill in our final blank spot, adding the champagne emoji to mark Zogenix’s big win.
As always, for more coverage of these companies (and many others), check out STAT Plus.
About the Author Reprints
